RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »


Technology and Solutions to Beat Cancer
The xCures technology platform automatically creates a comprehensive outline of a cancer patient's medical history generated from the hospitals and clinics visited. Patients get immediate access to the care summary and all of their medical data in one easy-to-access place, greatly facilitating the finding of promising treatment options.
For Patients
For Providers
Our DNA Is Patient-First Precision Oncology

At Cancer Commons we’ve helped thousands of patients with one-on-one research for the best treatment options. With xCures, we can help many, many more.
Erika Vial MonteverdiFormer Executive Director, Cancer Commons
“The program we ran on the xCures platform materially accelerated our development program of ONC201”
Wolfgang Oster MD, PhD
Founder Oncoceutics
Latest News
xCures Joins Big Names in Aetion’s New Initiative
xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. Aetion’s initiative will focus on better… Read more »
xCures Joins Big Names in Aetion’s New Initiative
xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. Aetion’s initiative will focus on better… Read more »